Suppr超能文献

连续联合激素治疗期间的乳腺钼靶密度、激素和生长因子。

Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy.

作者信息

Conner Peter, Svane Gunilla, Azavedo Edward, Söderqvist Gunnar, Carlström Kjell, Gräser Thomas, Walter Friedrich, von Schoultz Bo

机构信息

Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden.

出版信息

Fertil Steril. 2004 Jun;81(6):1617-23. doi: 10.1016/j.fertnstert.2004.02.096.

Abstract

OBJECTIVE

To study the effect on mammographic breast density of two different continuous combined regimens for hormone therapy.

DESIGN

Randomized clinical study.

SETTING

University hospital.

PATIENT(S): Postmenopausal women without any previous history of breast disorder.

INTERVENTION(S): The women received either estradiol valerate/dienogest or estradiol/norethisterone acetate. Mammograms and venous blood samples were obtained at baseline and after 6 months.

MAIN OUTCOME MEASURE(S): Change in mammographic breast density. Correlations with levels of hormones, growth factors, and binding proteins.

RESULT(S): An increase in mammographic density was recorded in approximately 50% of the women, and there were no differences between treatments. Increased density showed a positive correlation with estradiol, estrone, and sex hormone-binding globulin and showed a negative association to free T. Among hormonal factors, levels of free T were the most important for predicting increased density.

CONCLUSION(S): Continuous combined hormone therapy with different progestogens has a marked impact on the breast.

摘要

目的

研究两种不同的激素治疗连续联合方案对乳腺钼靶密度的影响。

设计

随机临床研究。

地点

大学医院。

患者

既往无任何乳腺疾病史的绝经后女性。

干预措施

女性接受戊酸雌二醇/地诺孕素或雌二醇/醋酸炔诺酮治疗。在基线时和6个月后进行乳腺钼靶检查并采集静脉血样本。

主要观察指标

乳腺钼靶密度的变化。与激素、生长因子和结合蛋白水平的相关性。

结果

约50%的女性乳腺钼靶密度增加,各治疗组之间无差异。密度增加与雌二醇、雌酮和性激素结合球蛋白呈正相关,与游离睾酮呈负相关。在激素因素中,游离睾酮水平对预测密度增加最为重要。

结论

不同孕激素的连续联合激素治疗对乳腺有显著影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验